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Abstract:  23 
GABAB receptors play a key role in regulating neuronal excitability in the brain. 24 
While the impact of somatic GABAB receptors on neuronal excitability has been 25 
studied in some detail, much less is known about the role of dendritic GABAB 26 
receptors. Here we investigate the impact of GABAB receptor activation on the 27 
somato-dendritic excitability of layer 5 pyramidal neurons in rat barrel cortex. 28 
Activation of GABAB receptors led to hyperpolarization and a decrease in membrane 29 
resistance, that was restricted largely to somatic or proximal dendritic locations. 30 
These effects were blocked by low concentrations of barium (100 µM), consistent 31 
with the idea that they are mediated by potassium channels. In contrast, activation of 32 
dendritic GABAB receptors decreased the width of backpropagating action potential 33 
(APs) and abolished dendritic calcium electrogenesis, indicating that dendritic 34 
GABAB receptors regulate excitability primarily via inhibition of voltage-dependent 35 
calcium channels. These distinct actions of somatic and dendritic GABAB receptors 36 
regulated neuronal output in different ways. Activation of somatic GABAB receptors 37 
led to a reduction in neuronal output primarily by increasing AP rheobase, whereas 38 
dendritic GABAB receptors blocking burst firing, decreasing the number of elicited 39 
APs in the absence of a significant change in somatic membrane properties. Taken 40 
together, our results show that GABAB receptors regulate somatic and dendritic 41 
excitability of cortical pyramidal neurons via different cellular mechanisms, with 42 
somatic GABAB receptors leading to a subtractive or shunting form of inhibition, 43 
whereas dendritic GABAB receptors reduce neuronal output via an inhibition of 44 
bursting firing. 45 
Key words: GABAB receptor, excitability, GIRK channels, calcium channels, output 46 
gain. 47 
48 
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Introduction: 49 
GABA is the primary inhibitory neurotransmitter in the brain. The release of GABA 50 
leads to fast postsynaptic inhibition mediated by the activation of GABAA receptors 51 
(Allen et al. 1977), whereas activation of GABAB receptors coupled to the G-protein 52 
Gi/o provides a mechanism for slow inhibition (Lüscher et al. 1997; Tamas et al. 53 
2003). This slow inhibition is though to be mediated via activation of G-protein 54 
coupled inwardly rectifying potassium channels (GIRK channels) belonging to the 55 
Kir3 potassium channel family (Chen and Johnston 2005; Gähwiler and Brown 1985; 56 
Lüscher et al. 1997; Newberry and Nicoll 1985). In addition, it has recently been 57 
shown that postsynaptic GABAB receptors can activate TREK-2 channels, a two pore-58 
domain potassium channel (Deng et al. 2009). By increasing membrane permeability 59 
to potassium, GABAB receptors play a crucial role in regulating neuronal excitability 60 
via hyperpolarizing the resting membrane potential and reducing the input resistance 61 
(Gähwiler and Brown 1985; Lüscher et al. 1997). In addition, GABAB receptors can 62 
act presynaptically to inhibit voltage-dependent calcium channels and thereby 63 
modulate transmitter release. While this action of GABAB receptors was initially 64 
thought to only be important in presynaptic terminals (Campbell et al. 1993; Mintz 65 
and Bean 1993; Scholz and Miller 1991), there is increasing evidence that GABAB 66 
receptors can also act to modulate voltage-dependent calcium channels in dendrites 67 
and spines (Chalifoux and Carter 2011; Kavalali et al. 1997; Sabatini and Svoboda 68 
2000), where they can influence dendritic excitability (Perez-Garci et al. 2006) as 69 
well as modulate NMDA receptor activation (Chalifoux and Carter 2010). 70 
 71 
The role these different forms of GABAB-mediated inhibition play in regulating 72 
neuronal output is less clear. Different classes of GABAergic neurons are known to 73 
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target different cellular compartments of cortical pyramidal neurons (Chu et al. 2003; 74 
Gonchar and Burkhalter 1999; 2003; Houser et al. 1983; Tamas et al. 2003; Zhu et al. 75 
2004). As such, it seems possible that somatic and dendritic GABAB receptors may 76 
regulate the excitability of cortical neurons in different ways. Further evidence for this 77 
idea comes from the observation that the function of the two varieties of the GABAB1 78 
subunit (GABAB1a and GABAB1b) are segregated, with the GABAB1a subunit 79 
mediating inhibition of voltage-dependent calcium channels, whereas the GABAB1b 80 
subunit being at least partly responsible for postsynaptic hyperpolarization (Perez-81 
Garci et al. 2006). 82 
 83 
Here we address the mechanisms by which somatic and dendritic GABAB receptors 84 
regulate the excitability of layer 5 pyramidal neurons in rat barrel cortex. We find that 85 
somatic excitability is regulated primarily via GABAB receptor activation of 86 
potassium channels, whereas dendritic excitability is regulated primarily via 87 
inhibition of voltage-dependent calcium channels, indicating that somatic and 88 
dendritic GABAB receptors regulate neuronal excitability via different mechanisms. 89 
90 
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Materials and methods: 91 
 92 
Slice preparation: 93 
All procedures are performed in accordance to methods approved by the Animal 94 
Ethics Committee of the Australian National University. Wistar rats (4 to 9 week old 95 
of either sex) were deeply anaesthetized by isoflurane inhalation (3% in oxygen) and 96 
decapitated. The brain was quickly removed and coronal slices containing barrel 97 
cortex prepared (300 µm thick). During this procedure, the brain was maintained in an 98 
ice-cold solution containing (in mM): 87 NaCl, 25 NaHCO3, 3 KCl, 1.25 NaH2PO4, 99 
0.5 CaCl2, 6 MgCl2, 25 Glucose, 75 Sucrose; pH=7.4; oxygenated with carbogen 100 
(95%O2/5%CO2). After cutting, slices were immersed in artificial cerebrospinal fluid 101 
(ACSF) containing (in mM): 125 NaCl, 25 NaHCO3, 3 KCl, 1.25 NaH2PO4, 2 CaCl2, 102 
1 MgCl2, 25 Glucose; pH= 7.4; oxygenated with carbogen (95%O2/5%CO2) and 103 
maintained at 35°C for 30 minutes, then stored at room temperature. The same ACSF 104 
solution was used for electrophysiological recording. 105 
 106 
Electrophysiological procedures: 107 
Barrel cortex slices were transferred to an immersed recording chamber continuously 108 
perfused with oxygenated ACSF (95%O2/5%CO2). Barrel cortex layer 5 was 109 
visualized under low magnification using an upright microscope (5x magnification; 110 
BX50WI, Olympus, Tokyo, Japan). Pyramidal neurons were observed at higher 111 
magnification (x60) using differential interference contrast (DIC) optics combined 112 
with infrared illumination (Stuart et al. 1993) allowing somatic and dendritic 113 
recordings under visual control. Somatic and dendritic patch pipettes were made from 114 
borosilicate glass (Harvard Appparatus, Edenbridge, Kent, UK) and pulled to obtain a 115 
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resistance of 5 and 10 MΩ, respectively. Whole-cell current-clamp recordings were 116 
obtained using glass pipettes filled with a potassium gluconate-based solution 117 
consisting of the following (in mM): 130 potassium gluconate, 10 KCl, 10 Hepes, 118 
4 MgATP, 0.3 Na2GTP, 10 Na2-phosphocreatine; pH= 7.3 with KOH and osmolarity 119 
set to 280 mosmol.l-1 with sucrose. Recordings were obtained at a temperature set at 120 
34 ± 1°C. 121 
 122 
Two identical BVC-700A current-clamp amplifiers (Dagan, Mineapolis, MN, USA) 123 
were used to record somatic and dendritic signals in the whole-cell configuration. 124 
These signals were digitized with an ITC-18 computer interface at 50 KHz 125 
(Instrutech, Port Washington, NY, USA), analogue filtered on-line at 10 KHz and 126 
acquired using the data acquisition software Axograph X (Axograph Scientific, 127 
Australia). The pipette bridge balance and capacitance were compensated on-line and 128 
checked throughout the experiment. Recordings where the somatic or dendritic access 129 
resistance exceeded 20 MΩ and 30 MΩ, respectively, have been discarded. 130 
Furthermore, only neurons with a stable resting membrane potential more negative 131 
than -65 mV were used. All membrane potentials have been corrected for the 132 
experimentally determined liquid junction potential of ~12 mV. 133 
 134 
Data analysis: 135 
The distance of dendritic recordings from the soma was estimated in situ using the 136 
linear distance between the somatic and the dendritic pipettes. The amplitude and the 137 
width of somatic and dendritic action potentials (APs) were measured from threshold, 138 
defined as a dV/dt of 50 and 25 mV/s, respectively. AP duration was measured at 139 
50% of peak amplitude. The amplitude of the medium after-hyperpolarization (AHP) 140 
 7
was defined as the voltage difference between AP threshold and the membrane 141 
potential 40 ms after AP onset. The rheobase was defined as the amplitude of the 142 
minimum somatic current required to elicit APs. The propagation velocity of 143 
backpropagated APs was determined from the time difference between the peak of 144 
somatic and dendritic APs. Somatic and dendritic input resistances were calculated 145 
from the fit to the linear region of the current-voltage relationship measured at 146 
steady-state during subthreshold current injections at somatic and dendritic recording 147 
sites, respectively. The critical frequency for dendritic calcium electrogenesis was 148 
determined during trains of five APs evoked via somatic current injection at 149 
frequencies ranging from 20 to 200 Hz (Larkum et al. 1999a). The integral of the 150 
dendritic response was plotted against the somatic AP frequency, and the critical 151 
frequency defined as previously described by Breton and Stuart (2009). The output 152 
gain of recorded neurons was analysed by fitting a linear function to the input-output 153 
relationship between the first four data points above the rheobase. Numerical values 154 
given in the text and figures represent mean ± S.E.M, and the level of statistical 155 
significance was set to P < 0.05. Statistical tests used in this study are indicated in the 156 
Results section. 157 
 158 
 159 
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Results: 160 
Recordings were obtained from rats aged 4 to 9 weeks of either sex (n= 80 neurons). 161 
As no significant difference was observed between male and female rats the data have 162 
been combined. 163 
 164 
Impact of GABAB receptor activation at the soma 165 
We first investigated the impact of GABAB receptor activation on the somatic resting 166 
membrane properties of layer 5 pyramidal neurons during bath application of baclofen 167 
(20 µM; a GABAB receptor agonist). Bath application of baclofen decreased the 168 
steady-state voltage response to hyperpolarizing somatic current injections compare to 169 
control (Fig. 1A, bottom). This led to a change in slope of the current-voltage 170 
relationship (Fig. 1B), indicating a reduction in input resistance (Rn) (Fig. 1D left; 171 
n= 42; P < 0.01, Tukey’s post hoc test). In parallel, GABAB receptor activation 172 
induced a significant hyperpolarization of the resting membrane potential (Vrest) 173 
(Fig. 1D, right; n= 42; P < 0.01, Tukey’s post hoc test). These effects of baclofen on 174 
somatic membrane properties were blocked by co-application of barium (Fig. 1D; 175 
100 µM), a wide spectrum blocker of potassium channels including GIRK channels, 176 
and by CGP52432 (1 µM), a potent GABAB receptor antagonist (n= 8; Fig. 1C). As 177 
the impact of baclofen was sensitive to low concentrations of barium these data 178 
suggest that GABAB receptors reduce somatic excitability via activation of a 179 
potassium conductance. 180 
 181 
Figure 1 near here 182 
 183 
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We also investigated the impact of GABAB receptor activation on active membrane 184 
properties at the soma. Supra-threshold current injections evoked regular and intrinsic 185 
bursting firing patterns similar to those observed in other studies (Breton and Stuart 186 
2009; Williams and Stuart 1999). Bath application of baclofen (20 µM) reduced the 187 
ability of layer 5 pyramidal neurons to generate action potentials (APs), shifting the 188 
input-output relationship (f/I relationship) to the right (Fig. 1A, E; table 1). This led to 189 
a significant decrease in the number of APs generated by supra-threshold current 190 
injections (1 nA; control: 31.0 ± 0.9 APs; baclofen: 17.1 ± 1.3 APs, n= 42; P < 0.001; 191 
Tukey’s post hoc test). Furthermore, bath application of baclofen converted intrinsic 192 
bursting neurons to regular firing neurons (n= 29 bursting neurons; Fig. 1A, top). 193 
Bath application of baclofen had a small but significant impact on somatic AP 194 
properties, leading to a slight reduction in AP amplitude, rate of rise and half-width 195 
without changing AP threshold (see table 1). These effects of baclofen were reversible 196 
after washing for at least 30 minutes (n= 23, data not shown) and were blocked by 197 
CGP52432 (1 µM; n= 8; data not shown). Co-application of baclofen (20 µM) with 198 
barium (100 µM) antagonized these effects of baclofen on the input-output properties 199 
of neurons (Fig. 1A, E; n= 42), suggesting it is mediated by activation of a potassium 200 
conductance. Furthermore, co-application of barium profoundly changed the firing 201 
properties of neurons, converting regular AP firing observed in baclofen to strong AP 202 
bursts (Fig. 1A). 203 
 204 
Table 1 near here 205 
 206 
Impact of dendritic GABAB receptor activation 207 
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To investigate the impact of GABAB receptors at somatic and dendritic sites, baclofen 208 
(50 µM) was focally applied (3 sec application) via a pipette placed in the vicinity of 209 
the somatic or dendritic recording pipette (within ~30 µm) during simultaneous 210 
somatic and dendritic recording. As seen during bath application, somatic application 211 
of baclofen evoked a hyperpolarization of the somatic membrane potential, which 212 
attenuated as it propagated to the dendritic recording site. Similarly, dendritic 213 
application of baclofen evoked a hyperpolarization of the dendritic membrane 214 
potential, which attenuated as it propagated to the somatic recording site (Fig. 2A). 215 
On average, however, the somatic response to somatic baclofen application was 216 
significantly larger than the dendritic response to dendritic baclofen application 217 
(Fig. 2B; dendritic baclofen applications 435 ± 23 µm from the soma; n= 12; 218 
P < 0.01, unpaired Student’s t test).  219 
 220 
Figure 2 near here 221 
 222 
To further study the effect of dendritic GABAB receptor activation on dendritic 223 
membrane excitability we examined the impact of bath application of baclofen 224 
(20 µM) on voltage responses to hyperpolarizing and depolarizing sub-threshold 225 
current injections at different apical dendritic locations. As seen at the soma, baclofen 226 
application lead to a decrease in the voltage response to hyperpolarizing dendritic 227 
current injections and a reduction in the slope of the I/V relationship, which was 228 
blocked by co-application of barium (Fig. 2C, D). This reduction in dendritic input 229 
resistance occurred in the absence of a significant change in dendritic membrane 230 
potential (control Vrest= -73.46 ± 1.00 mV; baclofen Vrest= -74.25 ± 0.73 mV; distance 231 
from soma: 395 ± 16 µm; n= 12; P > 0.05, paired Student’s t test). Furthermore, the 232 
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impact of bath application of baclofen on dendritic input resistance was distance 233 
dependent and only observed at proximal dendritic locations (Fig. 2E, F; two-way 234 
ANONA: effect of distance from soma: P= 0.0004 and effect of treatment: 235 
P < 0.0001; 100-300 µm: n= 9, 300-500 µm: n= 12; 500-800 µm: n= 9). Together, 236 
these results show that in layer 5 pyramidal neurons of the somatosensory cortex 237 
coupling of dendritic GABAB receptors to barium-sensitive potassium channels is 238 
restricted to proximal dendritic locations. 239 
 240 
Impact of GABAB receptor activation on steady-state voltage attenuation 241 
We next determined the impact of GABAB receptor activation on steady-state voltage 242 
attenuation during hyperpolarizing current injections (-450 pA, duration: 900 ms) at 243 
the soma or apical dendrite (Fig. 3A). Voltage attenuation was calculated as the ratio 244 
of the steady-state voltage response at the “receiving” location divided by that 245 
recorded at the site of current injection. Voltage attenuation from the soma to the 246 
dendritic recording site, and vice versa, was greater the larger the distance between 247 
the current injecting and receiving pipette due to the filtering properties of the apical 248 
dendrite (Fig. 3B, C). Importantly, however, we failed to observe an impact of bath 249 
application of baclofen (20 µM) on voltage attenuation irrespective of the direction of 250 
voltage spread (Fig. 3D; one-way ANOVA; n= 54; P= 0.4146 and P= 0.3494 for 251 
somatic and dendritic current injection, respectively). These data indicate that 252 
activation of dendritic GABAB receptors has minimal impact on steady-state voltage 253 
attenuation in layer 5 pyramidal neurons. 254 
 255 
Figure 3 near here 256 
 257 
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Impact of GABAB receptors activation on action potential backpropagation 258 
To understand the role of GABAB receptors in regulating active dendritic properties 259 
we first assessed their impact on backpropagating APs (bAPs) during dual somatic 260 
and dendritic whole-cell recordings (Fig. 4A). The amplitude of bAPs decreased as 261 
they invaded the apical dendrite and in some cases failed to propagate distally (Fig. 262 
4B, see Breton and Stuart 2009; Larkum et al. 2001; Stuart and Hausser 2001). Bath 263 
application of baclofen (20 µM) did not significantly affect the amplitude of bAPs at 264 
distal dendritic locations (Fig. 4B; control= 38.75 ± 3.44 mV, baclofen= 37.78 ± 3.56 265 
mV; distance from soma 520 ± 18 µm; n= 31; P > 0.05, paired Student’s t test). 266 
Furthermore, no significant impact of baclofen was observed on bAP velocity (Fig. 267 
4C; control= 0.41 ± 0.02 mV, baclofen= 0.43 ± 0.03 mV; n= 31; P > 0.05, paired 268 
Student’s t test) or rate of rise (Fig. 4D; control= 78.9 ± 8.8 mV.s-1, baclofen= 79.8 ± 269 
9.8 mV.s-1; n= 31; P > 0.05, paired Student’s t test). Bath application of baclofen (20 270 
µM) did, however, induce a distance-dependent decrease in bAPs duration (Fig. 4E, 271 
F). At distal dendritic location (520 ± 18 µm from the soma), baclofen (20 µM) 272 
significantly reduced bAP duration from 2.34 ± 0.14 ms (in control condition) to 1.67 273 
± 0.08 ms (n= 31; P < 0.001, paired Student’s t test). This effect was absent when 274 
baclofen was co-applied with the GABAB antagonist CGP52432 (1 µM, n= 8; Fig. 275 
4G) or low concentrations of nickel (100 µM), to block T- and R-type voltage-gated 276 
calcium channels (Fig. 4F, right; n= 8; P < 0.05, Tukey’s post hoc test). These data 277 
suggest that GABAB receptor activation causes a decrease in the duration of bAPs at 278 
distal locations by inhibiting dendritic T- and/or R-type voltage-gated calcium 279 
channels. 280 
 281 
Figure 4 near here 282 
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 283 
GABAB receptors inhibit dendritic calcium electrogenesis 284 
Given that baclofen reduced bAP duration by blocking dendritic calcium channels, we 285 
next investigated the impact of baclofen on dendritic calcium electrogenesis elicited 286 
by AP trains. Previous work indicates that trains of bAPs lead to generation of 287 
dendritic calcium electrogenesis in a frequency dependent manner as observed 288 
previously (Larkum et al. 1999a; Williams and Stuart 2000). The frequency of bAPs 289 
required to evoke dendritic calcium electrogenesis is called the “critical frequency” 290 
and can be used to determine the degree of dendritic excitability (Larkum et al. 291 
1999a). To examine the impact of GABAB receptor activation on dendritic 292 
excitability we therefore tested the effect of bath application of baclofen on the 293 
critical frequency. The dendritic response to trains of five somatic APs evoked at 294 
frequencies of 20 to 200 Hz (increment of 10 Hz) was recorded during dual dendritic 295 
and somatic whole-cell recording (Fig. 5A). In control, the observed critical 296 
frequency was 96.7 ± 3.1 Hz (n= 46), consistent with previous studies (Breton and 297 
Stuart 2009; Larkum et al. 1999a). Bath application of baclofen (20 µM) abolished 298 
dendritic calcium electrogenesis (Fig. 5B), leading to a significant decrease in the 299 
integral of dendritic responses measured at supra-critical frequencies (Fig. 5C, left; 300 
distance from soma: 518 ± 18 µm; n= 30, P < 0.001, paired Student’s t test). 301 
Furthermore, this effect of baclofen was blocked by CGP52432 (1 µM; n= 8; data not 302 
shown) and by low concentrations (100 µM) of nickel (Fig. 5C, right; n= 8).  303 
 304 
Figure 5 near here 305 
 306 
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Because bath application of baclofen activates both somatic and dendritic GABAB 307 
receptors, we tested the effect of local dendritic application of baclofen on the critical 308 
frequency. In these experiments a train of five somatic APs was generated at a supra-309 
critical frequency of 200 Hz and baclofen (50 µM) was applied locally in the vicinity 310 
of the dendritic recording pipette (with ~30 µm). Local application of baclofen to the 311 
dendritic recording location lead to a transient decrease in dendritic calcium 312 
electrogenesis, consistent with the idea that it is due to activation of dendritic GABAB 313 
receptors (Fig. 5D; control integral= 1.31 ± 0.07 mV.s; baclofen integral= 314 
1.03 ± 0.08 mV.s; n= 9; P < 0.001, paired Student’s t test). Together, these data show 315 
that activation of dendritic GABAB receptors decrease dendritic excitability by 316 
reducing dendritic calcium electrogenesis in layer 5 pyramidal neurons, presumably 317 
following down-regulation of dendritic T- and/or R-type voltage-gated calcium 318 
channels. 319 
 320 
Impact of somatic and dendritic GABAB receptors on neuronal output 321 
We next investigated how activation of GABAB receptors at different locations 322 
regulates neuronal output. In these experiments we recorded AP output in response to 323 
somatic current injections during local application of baclofen (50 µM) to the distal 324 
apical dendrite or to the soma. Local application of baclofen to distal dendritic 325 
locations (distance from soma 568 ± 12 µm; n= 7) failed to influence somatic resting 326 
membrane potential or input resistance (Fig. 6A; n= 7, P > 0.05, paired Student’s t 327 
test). These observations are in good agreement with the absence of a significant 328 
effect of bath application of baclofen on distal dendritic membrane properties 329 
(> 500 µm from the soma, see Fig. 2). Conversely, local application of baclofen to the 330 
soma lead to hyperpolarization of the somatic resting membrane potential and a 331 
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decrease in input resistance, similar to that seen during bath application of baclofen 332 
(Fig 6A; n= 7, Vrest: P < 0.01, Rn: P < 0.001, paired Student’s t test).  333 
 334 
Figure 6 near here 335 
 336 
Despite having no detectable impact on somatic resting membrane properties, 337 
activation of dendritic GABAB receptors reduced AP output during somatic current 338 
injections (Fig. 6B, G; distance from soma 568 ± 12 µm; n= 7). This was associated 339 
with a reduction in both AP burst firing (Fig. 6B, C; n= 7; P < 0.001, paired Student’s 340 
t test) and the number of APs elicited for a given current injection (Fig. 6G; current: 341 
+1000 pA; n=7; P < 0.05, paired Student’s t test), but no change in the slope of the 342 
input-output (f/I) relationship (Fig. 6D, F) and the rheobase (Fig. 6E) was observed. 343 
In contrast, activation of somatic GABAB receptors lead to an increase in both 344 
rheobase (Fig. 6E; n= 7; P < 0.001, paired Student’s t test) and the slope of the f/I 345 
relationship (Fig. 6F; n= 7; P < 0.01, paired Student’s t test), but no significant 346 
change on burst firing (Figure 6B,C). Somatic GABAB receptor activation was also 347 
associated with a significant decrease in the amplitude of the medium after-348 
hyperpolarization (AHP) following AP generation (Fig. 6H; n= 7; P < 0.01, paired 349 
Student’s t test). These results indicate that somatic GABAB receptor activation leads 350 
primarily to a reduction in AP output through an increase in the rheobase, whereas 351 
dendritic GABAB receptor activation reduces burst firing. 352 
353 
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Discussion: 354 
 355 
In this study we provide evidence that GABAB receptors regulate the somatic and 356 
dendritic excitability of layer 5 pyramidal neurons in the barrel cortex via different 357 
mechanisms. At the soma activation of GABAB receptors leads to a decrease in AP 358 
firing by hyperpolarizing the somatic resting membrane potential and decreasing the 359 
somatic membrane resistance via activation of putative GIRK channels. In contrast, at 360 
dendritic locations GABAB receptors reduce dendritic excitability primarily by down 361 
regulating dendritic calcium channels, leading to an increase in the threshold for 362 
generation of dendritic calcium electrogenesis and a decrease in burst firing. The 363 
consequence on neuronal output is a subtractive form of inhibition following 364 
activation of somatic and proximal dendritic GABAB receptors, whereas activation of 365 
distal dendritic GABAB receptors leads primarily to a divisive form of inhibition. 366 
 367 
Cellular mechanisms underlying GABAB-mediated slow inhibition 368 
Our results show that both bath and local somatic application of baclofen lead to 369 
hyperpolarization and a decrease in resistance at the soma of layer 5 pyramidal 370 
neurons. This effect is similar to that observed previously at the soma of neurons in 371 
other cortical areas and brain regions (Benardo 1994; Deng et al. 2009; Gähwiler and 372 
Brown 1985; Lüscher et al. 1997; Newberry and Nicoll 1985). Furthermore, we show 373 
that bath application of baclofen decreases neuronal excitability, as observed by a 374 
rightward shift of the input-output relationship (Fig. 1E). Similar results have been 375 
reported in neurons from the entorhinal cortex (Deng et al. 2009). These effects of 376 
GABAB receptors are likely to be due to activation of a potassium conductance. 377 
Previous studies indicate that GABAB receptors can activate G-protein coupled 378 
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inwardly rectifying potassium or GIRK (Kir3) channels (Chen and Johnston 2005; 379 
Lüscher et al. 1997; Takigawa and Alzheimer 1999). Consistent with this idea, 380 
GABAB-mediated slow inhibition is absent from hippocampal pyramidal neurons in 381 
the GIRK2 knockout mouse (Lüscher et al. 1997), although Deng et al. (2009) have 382 
recently described that GABAB receptors in entorhinal cortex can regulate neuronal 383 
excitability through activation of a TREK-2 (a two-pore domain) potassium channel. 384 
To investigate the contribution of GIRK channels to the effects observed in our study 385 
we co-applied baclofen with low concentrations of barium (100 µM), a non-selective 386 
blocker of GIRK channels (Chen and Johnston 2005; Coetzee et al. 1999; Takigawa 387 
and Alzheimer 1999). Application of baclofen with barium antagonized the effects of 388 
baclofen at the soma (Fig. 1), consistent with the idea that these effects are mediated 389 
by GIRK channels. That said, barium is quite non-specific even at low concentrations, 390 
hence we cannot rule out a role of TREK-2 or other potassium channels in mediating 391 
these effects of baclofen.  392 
 393 
Dendritic GABAB-mediated effects on input resistance at proximal dendritic locations 394 
were also barium-sensitive (Fig. 2), consistent with the idea that they are also 395 
mediated by GIRK channels. Activation of dendritic GIRK channels by GABAB 396 
receptors has previously been described in both cortical layer 5 and hippocampal 397 
pyramidal neurons (Chen and Johnston 2005; Takigawa and Alzheimer 1999). In our 398 
experiments the impact of baclofen on dendritic input resistance was restricted to 399 
proximal dendritic locations. This observation suggests that the baclofen-sensitive 400 
GIRK channel responses in the earlier work by Takigawa and Alzheimer (1999) are 401 
likely to be from proximal dendritic segments of cortical pyramidal neurons. In 402 
contrast, observations in hippocampal pyramidal neurons suggest that GABAB 403 
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receptors can activate GIRK channels also at distal dendritic locations (Chen and 404 
Johnston, 2005), where they may play a role in synaptic plasticity (Chen and Johnston 405 
2005; Chung et al. 2009). Consistent with this observation, an interplay between 406 
GABAB-activated GIRK channels and HCN channels has been observed in 407 
hippocampal pyramidal neurons (Takigawa and Alzheimer 2003), which are known to 408 
express HCN channels at high density in the distal apical dendrite (Magee 1999).  409 
 410 
Despite the capacity of baclofen to activate GIRK channels at proximal dendritic 411 
locations and at the soma, steady-state voltage attenuation was unaffected by bath 412 
application of balcofen irrespective of the direction of voltage spread (Fig. 3). While 413 
one might expect that steady-state voltage attenuation is relatively insensitive to 414 
changes in membrane resistance when voltage spreads away from the site of current 415 
injection, this should not be the case when voltage spreads towards the location of a 416 
decrease in membrane resistance. Yet no change in steady-state voltage attenuation 417 
was observed in our experiments. We predict this was the case as the change in 418 
voltage attenuation during baclofen applications was too small to be detected given 419 
the sensitivity of our experiments (unpublished simulations). Consistent with this 420 
idea, the density of GIRK channels at the soma and at proximal dendrite locations of 421 
CA1 hippocampal pyramidal neurons is low (Chen and Johnston 2005).  422 
 423 
GABAB-mediated modulation of dendritic excitability and calcium channels 424 
Action potentials attenuate and broaden as they propagate along the apical dendrite of 425 
cortical layer 5 pyramidal neurons (Stuart et al. 1997). Broadening of bAPs is in part 426 
due to activation of voltage-gated calcium channels, which also play a key role in 427 
generation of dendritic calcium electrogenesis that can feedback to the soma 428 
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triggering AP burst firing (Breton and Stuart 2009; Larkum et al. 1999a; Williams and 429 
Stuart 1999). Our data show that bath application of baclofen reduces the half-width 430 
of bAPs and abolishes dendritic calcium electrogenesis evoked by high frequency AP 431 
bursts (Fig. 4 & 5). This effect on dendritic excitability was mediated by GABAB 432 
receptors located at distal dendritic sites as it was observed during local dendritic 433 
applications of baclofen (Fig. 5D). These data suggest that dendritic GABAB 434 
receptors reduced dendritic excitability primarily through down regulation of 435 
dendritic voltage-gated calcium channels. Consistent with this idea, the impact of 436 
baclofen on bAP half-width and calcium electrogenesis during high-frequency AP 437 
firing was blocked in the presence of low concentrations of nickel (100 µM), which 438 
blocks T- and R-type voltage-gated calcium channels (Fig. 4F, 5C).  439 
 440 
Previous work indicates that activation of GABAergic input to somatosensory cortex 441 
can selectively block the initiation of dendritic calcium spikes (Larkum et al. 1999b). 442 
This effect involves, at least in part, the activation of dendritic GABAB receptors, 443 
through down regulation of dendritic calcium channels in layer 5 pyramidal neurons 444 
(Perez-Garci et al. 2006). Consistent with this earlier study, we also find that the 445 
impact of GABAB receptors on dendritic excitability in cortical pyramidal neurons is 446 
primarily via this mechanism. In addition, we find that the functional impact of 447 
GABAB-mediated inhibition of dendritic calcium channels and associated dendritic 448 
calcium electrogenesis is a reduction in burst firing at the soma (Fig. 1A, 6C). Given 449 
that AP burst firing is required for the induction of spike-timing-dependent plasticity 450 
(STDP) in layer 5 pyramidal neurons (Kampa et al. 2006; Letzkus et al. 2006), 451 
GABAB-receptor activation is likely to have a significant impact on STDP and other 452 
forms of NMDA receptor-dependent synaptic plasticity where the magnitude of the 453 
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dendritic depolarization associated with bAPs is key to removal of the voltage-454 
dependent magnesium block of NMDA receptors (Nowak et al. 1984). This action of 455 
GABAB receptors on synaptic plasticity will be further enhanced by the impact of 456 
GABAB-receptor activation on bAP duration (Fig. 4E, F). 457 
 458 
Impact of dendritic and somatic GABAB receptors on neuronal output 459 
With respect to the impact of GABAB receptors on neuronal output we show that 460 
distal dendritic baclofen applications decrease bursting firing, decreasing the number 461 
of APs elicited for suprathreshold current injections, in the absence of an impact on 462 
somatic membrane properties. This observation is consistent with the recent 463 
observations of Palmer et al. (2012), who also showed that GABAB receptor-mediated 464 
down-regulation of dendritic calcium channels leads to a reduction in AP firing in the 465 
absence of a significant change in somatic properties.  466 
 467 
In contrast, somatic baclofen applications increase AP rheobase, shifting the f/I 468 
relationship to the right without influencing AP bursting firing. This leads to a 469 
subtractive or shunting form of inhibition (Silver 2010). Interesting, activation of 470 
somatic GABAB receptors also leads to an increase the slope of the f/I relationship. 471 
This effect may be due to the impact of GABAB receptor activation on the medium 472 
AHP (Fig 6H). Consistent with this idea, previous work indicates a role of the AHP in 473 
regulation of output gain (Higgs et al. 2006). 474 
 475 
In summary, we show that GABAB receptors in cortical layer 5 pyramidal neurons act 476 
to decrease somatic and dendritic excitability via different mechanisms. Somatic 477 
GABAB receptors are coupled to barium-sensitive, putative GIRK potassium 478 
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channels, whereas dendritic GABAB receptors act primarily by down regulating 479 
dendritic calcium electrogenesis. As a result, activation of somatic GABAB receptors 480 
leads to a shift to the right of the f/I relationship and an increase in neuronal output 481 
gain, whereas activation of dendritic GABAB receptors causes a switch from burst to 482 
tonic firing, and a reduction in neuronal output. This location-dependent specificity of 483 
GABAB receptor activation on neuronal excitability would be expected to further 484 
enhance the diversity with which different GABAergic interneuronal cell types 485 
orchestrate network activity in the cortex. 486 
  487 
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Figure captions 624 
 625 
Figure 1: GABAB-mediated inhibition decreases somatic excitability. 626 
A, Responses of an intrinsically bursting layer 5 pyramidal neuron to subthreshold 627 
(bottom) and suprathreshold (top, lower traces shown responses on an expanded time 628 
scale) somatic current injection (top, middle traces; bottom, lower traces) in control 629 
(left), during bath application of baclofen (20 µM, middle), and following application 630 
of baclofen (20 µM) plus barium (100 µM, right). B, Impact of baclofen on the 631 
subthreshold I/V relationship (n= 42). Baclofen reduces the slope of the I/V curve 632 
compare to control, which is antagonized by barium. C, The GABAB-mediated 633 
change in the slope of the I/V curve is occluded by a prior application of the GABAB 634 
antagonist CGP52432 (1µM). D, Effect of baclofen or baclofen plus barium on 635 
somatic input resistance (left) and resting membrane potential (right). E, Impact of 636 
baclofen on the suptrathreshold input-output relationship (f/I curve). Baclofen causes 637 
a rightward shift in the f/I curve (n= 42), which is antagonized by barium. **: 638 
P < 0.01; ***: P < 0.001.  639 
 640 
Figure 2: The impact of GABAB receptors on resting membrane properties is 641 
restricted to somatic and proximal dendritic locations. 642 
A, Impact of local somatic (left) or dendritic (right) application of baclofen (50 µM, 643 
grey bar indicates application duration) on the somatic and dendritic membrane 644 
potential during dual somatic and dendritic recording (dendritic recording 410 µm 645 
from the soma). B, Average membrane potential hyperpolarization at the site of 646 
balcofen application. Dendritic recordings 435 ± 23 µm from the soma (n= 12). C, 647 
Dendritic voltage responses to dendritic current injection (bottom) in control and 648 
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following bath application of baclofen (20 µM). Bath application of baclofen (20 µM) 649 
decreased the amplitude of responses (C) and the slope of the I/V curve (D). These 650 
effects were antagonized by barium (100 µM). E, Distance-dependence of the 651 
decrease in dendritic input resistance during bath application of baclofen. Black and 652 
grey lines represent the linear fits to the data. F, Impact of bath application of 653 
balcofen (20 µM) on the dendritic input resistance at different dendritic locations. 654 
Balcofen significantly reduces the input resistance only at distances < 500 µm from 655 
the soma. **: P < 0.01; ***: P < 0.001; n.s.: non significant. 656 
 657 
Figure 3: GABAB receptor activation fails to influence steady-state attenuation. 658 
A, Somatic and dendritic (570 µm from the soma) responses recorded simultaneously 659 
during somatic current injection (-450 pA, 900 ms) in control (black) and bath 660 
application of baclofen (20 µM, grey). B, C, Steady-state attenuation measured at 661 
different locations along the apical dendrite during somatic (B) and dendritic (C) 662 
current injection. Steady-state attenuation calculated as the ratio of the steady-state 663 
voltage response recorded at the ”receiving” pipette divided by the response recorded 664 
at the site of current injection. D, Average steady-state attenuation in baclofen divided 665 
by that in control at different dendritic locations. No statistically significant impact of 666 
baclofen on steady-state voltage attenuation was observed irrespective of the site of 667 
dendritic recording or direction of steady-state voltage propagation. 668 
 669 
Figure 4: Impact of GABAB receptors on backpropagating APs. 670 
A, Example of somatic and backpropagating dendritic APs (bAPs; recorded 620 µm 671 
from the soma) in control (black) and following bath application of baclofen (grey; 672 
20 µM). Note the slight reduction in bAP width in baclofen. B-E, Graphs of the 673 
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distance dependence of bAP amplitude (B), velocity (C), rate-of-rise (D) and half-674 
width (E) in control (black) and during bath application of baclofen (grey, 20 µM). F, 675 
Left: The duration of bAPs is significantly decreased during bath application of 676 
baclofen (20 µM) at distal dendritic recording sites (dendritic recordings 520 ± 18 µm 677 
from the soma, n= 31). Right: In the presence of nickel (100 µM) baclofen no longer 678 
has an impact on bAP duration (dendritic recording 522 ± 30 µm from the soma, 679 
n= 8). G, The impact of baclofen (20 µM) on bAP width is blocked by the GABAB 680 
antagonist CGP52432 (1 µM).  *: P < 0.05; ***: P < 0.001; n.s.: non significant. 681 
 682 
Figure 5: GABAB receptors decrease dendritic calcium electrogenesis. 683 
A, Dendritic responses (620 µm from the soma) to trains of five APs evoked by 684 
somatic current injection (bottom) at the indicated frequencies in control (top) and 685 
following bath application of balcofen (20 µM, middle). B, Graph of dendritic voltage 686 
integral versus AP frequency for the data illustrated in A. Note the non-linear increase 687 
in dendritic integral in control (black), indicative of dendritic calcium electrogenesis, 688 
is abolished by baclofen (grey). C, The average dendritic voltage integral obtained at 689 
supra-critical frequencies (200 Hz) is significantly decreased in baclofen (left). This 690 
effect is occluded by a prior bath application of nickel (right; 100 µM). D, Dendritic 691 
responses (420 µm from the soma) during trains of somatic APs (5 spikes at 200Hz) 692 
at the times indicated in the graph (bottom) during local application of baclofen to the 693 
dendritic recording site (grey bar). **: P < 0.01; ***: P < 0.001; n.s.: non significant. 694 
 695 
Figure 6: Impact of somatic and dendritic GABAB receptors on somatic 696 
membrane properties and neuronal output. 697 
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A, Impact of somatic and dendritic baclofen application (50 µM) on somatic input 698 
resistance (left) and resting membrane potential (right). Note that dendritic application 699 
of baclofen does not affect somatic resting membrane properties (distance from soma 700 
568 ± 12 µm; n= 7). B, Examples of APs evoked by somatic current injection in a 701 
bursting (left) and a regular firing neuron (right). Dendritic application of baclofen 702 
(top traces) abolished AP burst firing in the bursting neuron (distance from soma 703 
560 µm) and reduced AP output in the regular firing neuron (distance from soma 704 
600 µm). Somatic application of baclofen (bottom traces) reduced AP output in both 705 
bursting and regular firing neurons, but did not block burst firing. The asterisks above 706 
the traces indicate APs bursts. C, Left, Examples of the impact of dendritic (top; 707 
distance from soma 540) and somatic (bottom) baclofen application on bursting firing 708 
neuron. Right, Average number of APs per burst in different experimental conditions 709 
(dendritic baclofen application: 568 ± 12 µm from the soma; n= 7). D, Input-output 710 
(f/I) curves from a typical neuron during somatic (left) and dendritic (right; distance 711 
from soma 630 µm) application of baclofen. E-G, Graphs of the average rheobase, 712 
slope of the f/I relationship and number of APs generated during a 1 nA current 713 
injection in different experimental conditions (dendritic baclofen application: 714 
568 ± 12 µm from the soma; n= 7). H, Impact of somatic application of baclofen on 715 
the medium AHP following an AP burst. *: P < 0.05; **: P < 0.01; ***: P < 0.001; 716 
n.s.: non significant. 717 
718 
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Table: 719 
 720 
Table 1: Effects of GABAB receptor activation on somatic AP properties. 721 
 Threshold 
(mV) 
Amplitude 
(mV) 
dV/dt 
(V.s-1) 
Half-width 
(ms) 
Rheobase 
(pA) 
n 
Control -59.4 ± 0.4 96.3 ± 0.5 634 ± 9 0.56 ± 0.01 275 ± 13 73 
Baclofen -59.5 ± 0.4 95.5 ± 0.5 619 ± 8 0.53 ± 0.01 522 ± 20 73 
Probability n.s. ** * ** ***  
Data are shown as mean ± S.E.M. n.s: non significant, *: P < 0.05; **: P < 0.01; ***: 722 
P < 0.001; paired Student’s t test. 723 
 724 
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